Emergent gains exclusive U.S./Canada commercial rights to Hikma's KLOXXADO 8 mg naloxone spray

Emergent BioSolutions Inc.

Six-year agreement gives Emergent exclusive rights to market and distribute KLOXXADO (naloxone HCl) 8 mg nasal spray in U.S. and Canada.
KLOXXADO complements existing OTC NARCAN 4 mg spray, offering higher-dose prescription option for opioid overdose reversal.
Hikma will continue manufacturing KLOXXADO; product will be integrated into Emergent's NARCANDirect distribution network.
CEO Joe Papa cites expanded product options to help reduce opioid overdose deaths and meet diverse patient and community needs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.